<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00552084</url>
  </required_header>
  <id_info>
    <org_study_id>543</org_study_id>
    <secondary_id>R01HL087254</secondary_id>
    <secondary_id>HL 087254</secondary_id>
    <nct_id>NCT00552084</nct_id>
  </id_info>
  <brief_title>Evaluating the Effectiveness of Fish Oil Supplements at Reducing the Recurrence of Atrial Fibrillation</brief_title>
  <official_title>Fish Oil for Atrial Fibrillation - Effect and Mechanisms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>eCardio Diagnostics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atrial fibrillation (AF) is a heart rhythm disorder that usually involves a rapid heart rate.&#xD;
      People who take fish oil supplements may reduce the risk of a recurrence of AF. This study&#xD;
      will evaluate the effectiveness of fish oil at decreasing the recurrence of AF and will&#xD;
      examine the reasons why fish oil may reduce this risk.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AF is the most common type of serious heart arrhythmia. It affects approximately 2% of the&#xD;
      population and is becoming more common. In AF, the heart's atria, or upper chambers, contract&#xD;
      in a very disorganized and abnormal manner and are unable to correctly pump blood into the&#xD;
      heart's ventricles, or lower chambers. Symptoms may include a rapid or irregular pulse,&#xD;
      dizziness, fainting, or breathing difficulty. Recent studies suggest that inflammation plays&#xD;
      a fundamental role in the development of AF. Inflammation, and the resulting oxidative&#xD;
      stress, can cause cellular and tissue damage. In turn, this may alter heart function,&#xD;
      potentially leading to both the onset and recurrence of AF. Markers of inflammation, such as&#xD;
      C-reactive protein (CRP) and interleukin-6 (IL-6), are often elevated in patients with AF,&#xD;
      providing further evidence of inflammation's role. While there are several treatment options&#xD;
      for AF, they are usually only moderately effective. Previous research has shown that fish oil&#xD;
      supplements have anti-inflammatory, antifibrotic, and antioxidant effects and can reduce the&#xD;
      risk of AF following surgery. However, it is not known exactly how fish oil reduces this risk&#xD;
      and whether the same positive effect will carry over in people who experience the more common&#xD;
      type of AF that is unrelated to surgery. The purpose of this study is to evaluate the&#xD;
      effectiveness of fish oil supplementation at decreasing the recurrence of AF in adults who&#xD;
      have not undergone recent surgery. Researchers will also examine the ways in which fish oil&#xD;
      reduces AF recurrence.&#xD;
&#xD;
      This study will enroll people who have had at least two occurrences of AF. Participants will&#xD;
      be randomly assigned to receive either fish oil supplements or placebo for 24 weeks. At study&#xD;
      visits at baseline and Weeks 2, 4, 8, 12, 18, and 24, participants will undergo a medical and&#xD;
      social history review, a physical exam, and blood and urine collection. At the baseline study&#xD;
      visit, an electrocardiogram will also occur.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Documented Recurrence of Atrial Fibrillation/Atrial Flutter</measure>
    <time_frame>Measured at Week 24 or exit</time_frame>
    <description>Trans-telephonic electrocardiographic monitoring (TTM) device were used to send transmissions every 2 weeks and each time a participant had symptoms suggestive of arrhythmia.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">190</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Fish Oil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 grams fish oil daily for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>corn oil taken daily for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fish oil</intervention_name>
    <description>Fish oil supplements 4 gms will be taken daily for 24 weeks.</description>
    <arm_group_label>Fish Oil</arm_group_label>
    <other_name>Lovaza capsule (1 gm)containing 465 mg EPA and 375 mg DHA.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo supplements will be taken daily for 24 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Corn oil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  &gt;=21 years of age&#xD;
&#xD;
          -  a history of atrial fibrillation&#xD;
&#xD;
          -  a history of at least two occurrences of atrial fibrillation or atrial flutter, at&#xD;
             least one of which is atrial fibrillation&#xD;
&#xD;
          -  an electrocardiogram that was recorded within 12 months of randomization showing&#xD;
             atrial fibrillation or atrial flutter&#xD;
&#xD;
          -  sinus rhythm at the time the first dose of randomized medication is taken&#xD;
&#xD;
          -  stable antiarrhythmic medications&#xD;
&#xD;
          -  if the patient has had an ablation for atrial fibrillation or flutter or a MAZE&#xD;
             procedure, the qualifying episode of atrial fibrillation must have occurred at least 3&#xD;
             months post-procedure&#xD;
&#xD;
          -  normal serum potassium level within the last 28 days&#xD;
&#xD;
          -  provided informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  permanent atrial fibrillation or flutter&#xD;
&#xD;
          -  New York Heart Association class III or IV heart failure or Canadian Cardiovascular&#xD;
             Society class III or IV angina pectoris&#xD;
&#xD;
          -  cardiac or thoracic surgery within the previous 3 months&#xD;
&#xD;
          -  acute pericarditis within the previous 3 months&#xD;
&#xD;
          -  other reversible causes of atrial fibrillation such as thyrotoxicosis&#xD;
&#xD;
          -  acute myocardial infarction or unstable angina within the previous 3 months&#xD;
&#xD;
          -  history of neurologic event (TIA or stroke)within the past 3 months&#xD;
&#xD;
          -  history of acute congestive heart failure precipitated by atrial fibrillation, and the&#xD;
             patient is not receiving rate-control therapy&#xD;
&#xD;
          -  Wolff-Parkinson-White syndrome&#xD;
&#xD;
          -  a medical condition that is likely to be fatal in less than one year&#xD;
&#xD;
          -  active, uncontrolled co-morbid inflammatory condition (e.g., rheumatoid arthritis,&#xD;
             inflammatory bowel disease, SLE)&#xD;
&#xD;
          -  receiving cytotoxic chemotherapy or radiotherapy for cancer&#xD;
&#xD;
          -  taking a fish oil supplement&#xD;
&#xD;
          -  allergic to fish&#xD;
&#xD;
          -  bleeding event not related to trauma or surgery requiring hospitalization or&#xD;
             transfusion in previous year&#xD;
&#xD;
          -  systolic blood pressure &lt; 90 mm Hg or heart rate &lt;50 beats/minute&#xD;
&#xD;
          -  history of ventricular fibrillation or sustained ventricular tachycardia, or presence&#xD;
             of an implanted defibrillator placed for the occurrence of such an event or the&#xD;
             presence of an Implantable Cardioverter-Defibrillator (ICD) that has discharged&#xD;
             appropriately for a ventricular arrhythmia&#xD;
&#xD;
          -  pregnant or breast feeding&#xD;
&#xD;
          -  enrollment in another research study involving an intervention&#xD;
&#xD;
          -  on dialysis or recipient of a renal transplant&#xD;
&#xD;
          -  use of potentially cardiotoxic illegal drugs (cocaine, methamphetamine, opioids) in&#xD;
             the last 12 months&#xD;
&#xD;
          -  Treated for alcoholism and currently drinking alcohol to excess or alcoholic&#xD;
             cardiomyopathy as the primary clinical diagnosis and currently drinking alcohol to&#xD;
             excess&#xD;
&#xD;
          -  presence of an iron-storage disease, such as hemochromatosis, transfusional&#xD;
             hemosiderosis, or those subjects in whom a daily dose of up to 20 mg elemental iron&#xD;
             (in and of itself or in addition of current iron supplementation) would post a risk&#xD;
             for toxicity from iron overload&#xD;
&#xD;
          -  subjects receiving or anticipated to receive intravenous iron therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles M. Stein</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt Medical School</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <study_first_submitted>October 31, 2007</study_first_submitted>
  <study_first_submitted_qc>October 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2007</study_first_posted>
  <results_first_submitted>November 10, 2014</results_first_submitted>
  <results_first_submitted_qc>November 10, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 18, 2014</results_first_posted>
  <last_update_submitted>November 18, 2014</last_update_submitted>
  <last_update_submitted_qc>November 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>C. Michael Stein</investigator_full_name>
    <investigator_title>Dan May Professor of Medicine, Professor of Pharmacology, Assistant Director of the Division of Clinical Pharmacology</investigator_title>
  </responsible_party>
  <keyword>Fish Oil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited at 4 medical centers in Nashville Tennessee, and at the Marsh field Clinic in Madison, Wisconsin. Between December 2007 and December 2012, 241 patients were enrolled and 190 (178 at Vanderbilt, 12 at other sites) were randomized to fish oil (126) or placebo (64). Of 190 enrolled, 173 (91%) completed the study.</recruitment_details>
      <pre_assignment_details>Patients were &gt;= 21 years old with a history of at least 2 occurrences of atrial fibrillation or atrial flutter, and in sinus rhythm at randomization. Randomization was performed according to a computer-generated block scheme according to anti-arrhythmic therapy: 1. no therapy, 2. amiodarone, 3. class 1 anti-arrhythmic drugs, 4.sotalol/dofetilide.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Fish Oil</title>
          <description>4 grams fish oil daily for 24 weeks&#xD;
Fish oil: Fish oil supplements 4 gms will be taken daily for 24 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>corn oil taken daily for 24 weeks&#xD;
Placebo: Placebo supplements will be taken daily for 24 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="126"/>
                <participants group_id="P2" count="64"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="118"/>
                <participants group_id="P2" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>change in anti-arrythmic drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fish Oil</title>
          <description>4 grams fish oil daily for 24 weeks&#xD;
Fish oil: Fish oil supplements 4 gms will be taken daily for 24 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>corn oil taken daily for 24 weeks&#xD;
Placebo: Placebo supplements will be taken daily for 24 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="126"/>
            <count group_id="B2" value="64"/>
            <count group_id="B3" value="190"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.9" lower_limit="21" upper_limit="82"/>
                    <measurement group_id="B2" value="61.5" lower_limit="28" upper_limit="82"/>
                    <measurement group_id="B3" value="61.7" lower_limit="21" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="81"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Documented Recurrence of Atrial Fibrillation/Atrial Flutter</title>
        <description>Trans-telephonic electrocardiographic monitoring (TTM) device were used to send transmissions every 2 weeks and each time a participant had symptoms suggestive of arrhythmia.</description>
        <time_frame>Measured at Week 24 or exit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fish Oil</title>
            <description>4 grams fish oil daily for 24 weeks&#xD;
Fish oil: Fish oil supplements 4 gms will be taken daily for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>corn oil taken daily for 24 weeks&#xD;
Placebo: Placebo supplements will be taken daily for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Documented Recurrence of Atrial Fibrillation/Atrial Flutter</title>
          <description>Trans-telephonic electrocardiographic monitoring (TTM) device were used to send transmissions every 2 weeks and each time a participant had symptoms suggestive of arrhythmia.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected during the 24 week study, after participants took first dose of study medication or placebo.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Fish Oil</title>
          <description>4 grams fish oil daily for 24 weeks&#xD;
Fish oil: Fish oil supplements 4 gms will be taken daily for 24 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>corn oil taken daily for 24 weeks&#xD;
Placebo: Placebo supplements will be taken daily for 24 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>acute coronary syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>rapid atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>pseudogout</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Low INR</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>We determined recurrence of Atrial Fibrillation(AF) by both routine and symptomatic TTM transmissions. We did not examine the effect of therapy on total AF burden. Sample size was relatively small, and included a heterogeneous patient population.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. C Michael Stein</name_or_title>
      <organization>Vanderbilt University Medical Center</organization>
      <phone>615-936-3420</phone>
      <email>mike.stein@vanderbilt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

